Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 918 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervix Neoplasms Clear all
Completed Phase 1 Interventional

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

NCT05712889
View directory record Official record
Conditions
Neoplasms
Interventions
VIP236 (Q3W), VIP236 (Q2W)
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 30, 2026, 2:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems

NCT06843720
View directory record Official record
Conditions
HR-HPV Testing
Interventions
HR-HPV Testing
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
7,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination

NCT04452526
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus-Related Malignant Neoplasm
Interventions
Best Practice, Educational Intervention, Questionnaire Administration, Reminder
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
11 Years and older
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
4
States / cities
Lexington, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

NCT03023319
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer, Peritoneal Cancer, Thymoma, Thymus Cancer, Uterine Cervical Cancer
Interventions
Bosutinib, Pemetrexed
Drug
Lead sponsor
Nagla Abdel Karim
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 30, 2026, 2:38 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Self-Collected Swabs for Primary Human Papilloma Virus (HPV) Screening

NCT05989464
View directory record Official record
Conditions
HPV
Interventions
Self-swab for genital HPV
Diagnostic Test
Lead sponsor
University of Hawaii
Other
Eligibility
25 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 30, 2026, 2:38 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

NCT05325866
View directory record Official record
Conditions
Solid Tumors
Interventions
Bemarituzumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Duarte, California • Orange, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia

NCT00075569
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
HspE7
Biological
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Not applicable Interventional

PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery

NCT00003429
View directory record Official record
Conditions
Cervical Cancer
Interventions
biopsy, computed tomography, positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cervical Cancer Self-Collection for Southeast Asian Immigrant and Refugee Women

NCT05286749
View directory record Official record
Conditions
Cervical Cancer Screening
Interventions
Workshop plus Clinician-Collected Cervical Swab, Workshop plus Participant-Collected Cervical Swab, HPV testing on Participant-Collected Cervical Swab Samples
Procedure · Device · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 2:38 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

NCT07182149
View directory record Official record
Conditions
HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer (TNBC)
Interventions
NRM-823
Drug
Lead sponsor
Normunity AccelCo, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Image-Guided Gynecologic Brachytherapy

NCT01399658
View directory record Official record
Conditions
Cervical Cancer, Uterine Cancer, Vaginal Cancer, Carcinoma of the Vulva
Interventions
Image-guided brachytherapy, 3'-Deoxy-3'-18f-Fluorothymidine
Procedure · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 30, 2026, 2:38 PM EDT
Not listed Phase 1 Interventional

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

NCT03634982
View directory record Official record
Conditions
Solid Tumors
Interventions
RMC-4630
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women

NCT00376909
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer
Interventions
educational intervention, study of socioeconomic and demographic variables
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
2,729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
2
States / cities
Lebanon, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 30, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

NCT03894215
View directory record Official record
Conditions
Cervical Cancer
Interventions
AGEN2034, AGEN1884
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals

NCT03222817
View directory record Official record
Conditions
Cervical Cancer Screening
Interventions
HPV self-sampling
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 30, 2026, 2:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

NCT06611540
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Louisville, Kentucky • Ann Arbor, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Not listed Phase 1 Interventional

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NCT05311618
View directory record Official record
Conditions
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Cancer, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Interventions
NGM438, Pembrolizumab (KEYTRUDA ®)
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Not applicable Interventional

Breast and Cervical Cancer Education Program

NCT06365450
View directory record Official record
Conditions
Cervical Cancer, Breast Cancer, Health Behavior
Interventions
Educational Intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

NCT03841110
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
Interventions
FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prospective Evaluation of Self-Testing to Increase Screening

NCT03898167
View directory record Official record
Conditions
Cervical Cancer, Human Papillomavirus Infection
Interventions
Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
2,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 30, 2026, 2:38 PM EDT
Completed Not applicable Interventional

Using a Lay Health Worker Program to Increase Breast and Cervical Cancer Screening in Low-Income Hispanic Women

NCT04426019
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer
Interventions
CLS Intervention, No CLS intervention
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older · Female only
Enrollment
1,025 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 30, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

NCT07770100
View directory record Official record
Conditions
Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC)
Interventions
Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab, Atezolizumab, Ipilimumab
Radiation · Drug
Lead sponsor
Mark Bernard
Other
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 2:38 PM EDT
Terminated Early Phase 1 Interventional Results available

E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer

NCT04476251
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
E7 T-Cell Receptor (TCR)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 30, 2026, 2:38 PM EDT
Completed No phase listed Observational

Molecular Imaging for Detection of Cervical Intraepithelial Neoplasia

NCT00511615
View directory record Official record
Conditions
Cervical Cancer
Interventions
Loop Electrosurgical Excision Procedure (LEEP)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 30, 2026, 2:38 PM EDT